Similar articles

• The pharmacology of leishmaniasis.

  Balaña-Fouce R, Reguera RM, Cubría JC, Ordóñez D. Balaña-Fouce R, et al. Gen Pharmacol. 1998 Apr;30(4):435-43. doi: 10.1016/s0306-3623(97)00268-1. Gen Pharmacol. 1998. PMID: 9580315 Review.
• Clinical status of agents being developed for leishmaniasis.

  Berman J. Berman J. Expert Opin Investig Drugs. 2005 Nov;14(11):1337-46. doi: 10.1517/13543784.14.11.1337. Expert Opin Investig Drugs. 2005. PMID: 16255674 Review.
• Comment on: leishmaniasis: an update of current pharmacotherapy.

  Arya SC, Agarwal N. Arya SC, et al. Expert Opin Pharmacother. 2013 Jun;14(9):1275-6. doi: 10.1517/14656566.2013.795544. Epub 2013 Apr 29. Expert Opin Pharmacother. 2013. PMID: 23621855 No abstract available.
• [Therapeutic options for visceral leishmaniasis].

  Desjeux P. Desjeux P. Med Mal Infect. 2005 Jun;35 Suppl 2:S74-6. doi: 10.1016/s0399-077x(05)80887-x. Med Mal Infect. 2005. PMID: 15978396 French. No abstract available.
• Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.

  Manfredi R, Marinacci G, Calza L, Passarini B. Manfredi R, et al. Int J Antimicrob Agents. 2008 Jun;31(6):590-2. doi: 10.1016/j.ijantimicag.2008.02.007. Epub 2008 May 5. Int J Antimicrob Agents. 2008. PMID: 18456464 No abstract available.